{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:07Z","timestamp":1747207327622,"version":"3.40.5"},"reference-count":141,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Huntington\u2019s disease (HD) is a progressive neurodegenerative disorder which deteriorates\nthe physical and mental abilities of the patients. It is an autosomal dominant disorder and is\nmainly caused by the expansion of a repeating CAG triplet. A number of animal models ranging\nfrom worms, fruit flies, mice and rat, pig, sheep and monkeys are available, which have been helpful\nin understanding various pathways involved during the progression of the disease. Drosophila\nis one of the most commonly used model organisms for biomedical science, due to low cost maintenance,\nshort life span and easy implications of genetic tools. The present review provides a brief description\nof HD and the studies carried out for HD to date, taking Drosophila as a model.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527320666210412155508","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T05:47:56Z","timestamp":1618292876000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modulation of Huntington\u2019s Disease in Drosophila"],"prefix":"10.2174","volume":"20","author":[{"given":"Iqra","family":"Subhan","sequence":"first","affiliation":[{"name":"Department of Zoology, Drosophila Transgenic Laboratory, Section of Genetics, Faculty of Life Sciences, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-3900","authenticated-orcid":true,"given":"Yasir Hasan","family":"Siddique","sequence":"additional","affiliation":[{"name":"Department of Zoology, Drosophila Transgenic Laboratory, Section of Genetics, Faculty of Life Sciences, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"year":"2018","author":"Caron N.S.","key":"ref=1","unstructured":"Caron N.S.; Wright G.E.; Hayden M.R.;  2018"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4161\/fly.26279","volume":"7","author":"Krench M.","year":"2013","unstructured":"Krench M.; Littleton J.T.; Modeling Huntington disease in Drosophila: Insights into axonal transport defects and modifiers of toxicity. Fly (Austin) 2013,7(4),229-236","journal-title":"Fly (Austin)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos R.A.","year":"2010","unstructured":"Roos R.A.; Huntington\u2019s disease: A clinical review. Orphanet J Rare Dis 2010,5,40","journal-title":"Orphanet J Rare Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"Walker F.O.","year":"2007","unstructured":"Walker F.O.; Huntington\u2019s disease. Lancet 2007,369(9557),218-228","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10863-010-9288-5","volume":"42","author":"Pandey M.","year":"2010","unstructured":"Pandey M.; Mohanakumar K.P.; Usha R.; Mitochondrial functional alterations in relation to pathophysiology of Huntington\u2019s disease. J Bioenerg Biomembr 2010,42(3),217-226","journal-title":"J Bioenerg Biomembr"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"Reiner A.","year":"2011","unstructured":"Reiner A.; Dragatsis I.; Dietrich P.; Genetics and neuropathology of Huntington\u2019s disease. Int Rev Neurobiol [Academic Press.].2011,98,325-372","journal-title":"Int Rev Neurobiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1570-8703.2006.00474.x","volume":"121","author":"Roberts D.B.","year":"2006","unstructured":"Roberts D.B.; Drosophila melanogaster: The model organism. Entomol Exp Appl 2006,121,93-103","journal-title":"Entomol Exp Appl"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.cdd.4400757","volume":"7","author":"Chan H.Y.","year":"2000","unstructured":"Chan H.Y.; Bonini N.M.; Drosophila models of human neurodegenerative disease. Cell Death Differ 2000,7(11),1075-1080","journal-title":"Cell Death Differ"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-0529-0_1","author":"Yamaguchi M.","year":"2018","unstructured":"Yamaguchi M.; Yoshida H.;  Drosophila models for human diseases 2018","journal-title":"Drosophila models for human diseases"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2010_110","author":"O\u2019Kane C.J.","year":"2011","unstructured":"O\u2019Kane C.J.;  Molecular and functional models in neuropsychiatry 2011","journal-title":"Molecular and functional models in neuropsychiatry"},{"key":"ref=11","first-page":"425","volume":"18","author":"Wan Y.","year":"2006","unstructured":"Wan Y.; Xie W.; Drosophila: An important model organism for understanding basic biological and human disease mechanisms. Chinese Bull Life Sci 2006,18(5),425","journal-title":"Chinese Bull Life Sci"},{"key":"ref=12","author":"Lindsley D.L.","year":"2012","unstructured":"Lindsley D.L.; Zimm G.G.;  The genome of Drosophila melanogaster 2012","journal-title":"The genome of Drosophila melanogaster"},{"key":"ref=13","author":"Reiter L.T.","year":"2001","unstructured":"Reiter L.T.; Drosophila as a model for human diseases. e LS 2001","journal-title":"e LS"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrn751","volume":"3","author":"Muqit M.M.","year":"2002","unstructured":"Muqit M.M.; Feany M.B.; Modelling neurodegenerative diseases in Drosophila: A fruitful approach? Nat Rev Neurosci 2002,3(3),237-243","journal-title":"Nat Rev Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuron.2006.09.025","volume":"52","author":"Marsh J.L.","year":"2006","unstructured":"Marsh J.L.; Thompson L.M.; Drosophila in the study of neurodegenerative disease. Neuron 2006,52(1),169-178","journal-title":"Neuron"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1602\/neurorx.2.3.438","volume":"2","author":"Sang T.K.","year":"2005","unstructured":"Sang T.K.; Jackson G.R.; Drosophila models of neurodegenerative disease. NeuroRx 2005,2(3),438-446","journal-title":"NeuroRx"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1124\/pr.110.003293","volume":"63","author":"Pandey U.B.","year":"2011","unstructured":"Pandey U.B.; Nichols C.D.; Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev 2011,63(2),411-436","journal-title":"Pharmacol Rev"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1471-4892(02)00206-0","volume":"2","author":"Tickoo S.","year":"2002","unstructured":"Tickoo S.; Russell S.; Drosophila melanogaster as a model system for drug discovery and pathway screening Current opinion in pharmacology 2002,2,555-560","journal-title":"Current opinion in pharmacology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4161\/fly.3.1.7774","volume":"3","author":"Bell A.J.","year":"2009","unstructured":"Bell A.J.; McBride S.M.; Dockendorff T.C.; Flies as the ointment: Drosophila modeling to enhance drug discovery. Fly (Austin) 2009,3(1),39-49","journal-title":"Fly (Austin)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1517\/17460441.2013.849691","volume":"8","author":"Konsolaki M.","year":"2013","unstructured":"Konsolaki M.; Fruitful research: Drug target discovery for neurodegenerative diseases in Drosophila. Expert Opin Drug Discov 2013,8(12),1503-1513","journal-title":"Expert Opin Drug Discov"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/17460441.2011.549124","volume":"6","author":"Newman T.","year":"2011","unstructured":"Newman T.; Sinadinos C.; Johnston A.; Sealey M.; Mudher A.; Using Drosophila models of neurodegenerative diseases for drug discovery Expert Opin Drug Discov 2011,6,129-140","journal-title":"Expert Opin Drug Discov"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","volume":"12","author":"Kennedy L.","year":"2003","unstructured":"Kennedy L.; Evans E.; Chen C.M.; Craven L.; Detloff P.J.; Ennis M.; Shelbourne P.F.; Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 2003,12(24),3359-3367","journal-title":"Hum Mol Genet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1357-4310(00)01761-5","volume":"6","author":"Wanker E.E.","year":"2000","unstructured":"Wanker E.E.; Protein aggregation in Huntington\u2019s and Parkinson\u2019s disease: Implications for therapy. Mol Med Today 2000,6(10),387-391","journal-title":"Mol Med Today"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"Ross C.A.","year":"2011","unstructured":"Ross C.A.; Tabrizi S.J.; Huntington\u2019s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol 2011,10(1),83-98","journal-title":"Lancet Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","volume":"198","author":"Raymond L.A.","year":"2011","unstructured":"Raymond L.A.; Andr\u00e9 V.M.; Cepeda C.; Gladding C.M.; Milnerwood A.J.; Levine M.S.; Pathophysiology of Huntington\u2019s disease: Time-dependent alterations in synaptic and receptor function. Neuroscience 2011,198,252-273","journal-title":"Neuroscience"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/NDT.S6430","volume":"6","author":"Frank S.","year":"2010","unstructured":"Frank S.; Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010,6,657-665","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1073\/pnas.0500055102","volume":"102","author":"Agrawal N.","year":"2005","unstructured":"Agrawal N.; Pallos J.; Slepko N.; Apostol B.L.; Bodai L.; Chang L.W.; Chiang A.S.; Thompson L.M.; Marsh J.L.; Identification of combinatorial drug regimens for treatment of Huntington\u2019s disease using Drosophila. Proc Natl Acad Sci USA 2005,102(10),3777-3781","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","volume":"47","author":"Girotti F.","year":"1984","unstructured":"Girotti F.; Carella F.; Scigliano G.; Grassi M.P.; Soliveri P.; Giovannini P.; Parati E.; Caraceni T.; Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 1984,47(8),848-852","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/hmg\/ddm294","volume":"17","author":"Sarkar S.","year":"2008","unstructured":"Sarkar S.; Krishna G.; Imarisio S.; Saiki S.; O\u2019Kane C.J.; Rubinsztein D.C.; A rational mechanism for combination treatment of Huntington\u2019s disease using lithium and rapamycin. Hum Mol Genet 2008,17(2),170-178","journal-title":"Hum Mol Genet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"Duff K.","year":"2008","unstructured":"Duff K.; Beglinger L.J.; O\u2019Rourke M.E.; Nopoulos P.; Paulson H.L.; Paulsen J.S.; Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry 2008,20(1),1-3","journal-title":"Ann Clin Psychiatry"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"Bonelli R.M.","year":"2006","unstructured":"Bonelli R.M.; Wenning G.K.; Pharmacological management of Huntington\u2019s disease: An evidence-based review. Curr Pharm Des 2006,12(21),2701-2720","journal-title":"Curr Pharm Des"},{"key":"ref=32","first-page":"545","volume":"3","author":"Paleacu D.","year":"2007","unstructured":"Paleacu D.; Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat 2007,3(5),545-551","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"Coppen E.M.","year":"2017","unstructured":"Coppen E.M.; Roos R.A.; Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs 2017,77(1),29-46","journal-title":"Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/14656566.8.2.141","volume":"8","author":"Bonelli R.M.","year":"2007","unstructured":"Bonelli R.M.; Hofmann P.; A systematic review of the treatment studies in Huntington\u2019s disease since 1990. Expert Opin Pharmacother 2007,8(2),141-153","journal-title":"Expert Opin Pharmacother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","volume":"15","author":"Videnovic A.","year":"2013","unstructured":"Videnovic A.; Treatment of huntington disease. Curr Treat Options Neurol 2013,15(4),424-438","journal-title":"Curr Treat Options Neurol"},{"key":"ref=36","author":"Almeida S.A.R.D.","year":"2012","unstructured":"Almeida S.A.R.D.;  Gait disorders in Parkinson\u2019s and Huntington\u2019s diseases (Master's thesis)2012","journal-title":"Gait disorders in Parkinson\u2019s and Huntington\u2019s diseases"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s002130000575","volume":"153","author":"De Marchi N.","year":"2001","unstructured":"De Marchi N.; Daniele F.; Ragone M.A.; Fluoxetine in the treatment of Huntington\u2019s disease. Psychopharmacol (Berl) 2001,153(2),264-266","journal-title":"Psychopharmacol (Berl)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","volume":"12","author":"Van Duijn E.","year":"2010","unstructured":"Van Duijn E.; Treatment of irritability in Huntington\u2019s disease. Curr Treat Options Neurol 2010,12(5),424-433","journal-title":"Curr Treat Options Neurol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mds.25750","volume":"29","author":"Beglinger L.J.","year":"2014","unstructured":"Beglinger L.J.; Adams W.H.; Langbehn D.; Fiedorowicz J.G.; Jorge R.; Biglan K.; Caviness J.; Olson B.; Robinson R.G.; Kieburtz K.; Paulsen J.S.; Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 2014,29(3),401-405","journal-title":"Mov Disord"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","volume":"35","author":"Koller W.C.","year":"1985","unstructured":"Koller W.C.; Trimble J.; The gait abnormality of Huntington\u2019s disease. Neurology 1985,35(10),1450-1454","journal-title":"Neurology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1176\/jnp.8.3.338","volume":"8","author":"Ranen N.G.","year":"1996","unstructured":"Ranen N.G.; Lipsey J.R.; Treisman G.; Ross C.A.; Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 1996,8(3),338-340","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nbd.2007.07.028","volume":"29","author":"Charvin D.","year":"2008","unstructured":"Charvin D.; Roze E.; Perrin V.; Deyts C.; Betuing S.; Pag\u00e8s C.; R\u00e9gulier E.; Luthi-Carter R.; Brouillet E.; D\u00e9glon N.; Caboche J.; Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol Dis 2008,29(1),22-29","journal-title":"Neurobiol Dis"},{"key":"ref=43","first-page":"649","volume":"97","author":"Margolis R.L.","year":"2003","unstructured":"Margolis R.L.; Ross C.A.; Clinical chemistry, 49(10), 1726-1732. Pasini ME, Paiardi C, Vernizzi L, et al. Pandey M, Rajamma U. Huntington\u2019s disease: The coming of age. J Genet 2003,97,649-664","journal-title":"J Genet"},{"key":"ref=44","first-page":"26","volume":"13","author":"Krupanidhi Srirama J.V.","year":"2019","unstructured":"Krupanidhi Srirama J.V.; Tejaswi K.; Thanmayi M.N.; Huntington\u2019s chorea, a neurological disorder of all ages\u2013Bioinformatics approach for its precise diagnosis. Int J Health Sci 2019,13,26","journal-title":"Int J Health Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"Paulsen J.S.","year":"2008","unstructured":"Paulsen J.S.; Langbehn D.R.; Stout J.C.; Aylward E.; Ross C.A.; Nance M.; Guttman M.; Johnson S.; MacDonald M.; Beglinger L.J.; Duff K.; Kayson E.; Biglan K.; Shoulson I.; Oakes D.; Hayden M.; Detection of Huntington\u2019s disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry 2008,79(8),874-880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/mds.26011","volume":"29","author":"Reilmann R.","year":"2014","unstructured":"Reilmann R.; Leavitt B.R.; Ross C.A.; Diagnostic criteria for Huntington\u2019s disease based on natural history. Mov Disord 2014,29(11),1335-1341","journal-title":"Mov Disord"},{"key":"ref=47","first-page":"359","volume":"19","author":"Purdon S.E.","year":"1994","unstructured":"Purdon S.E.; Mohr E.; Ilivitsky V.; Jones B.D.; Huntington\u2019s disease: Pathogenesis, diagnosis and treatment. J Psychiatry Neurosci 1994,19(5),359-367","journal-title":"J Psychiatry Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/hmg\/9.1.13","volume":"9","author":"Marsh J.L.","year":"2000","unstructured":"Marsh J.L.; Walker H.; Theisen H.; Zhu Y.Z.; Fielder T.; Purcell J.; Thompson L.M.; Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000,9(1),13-25","journal-title":"Hum Mol Genet"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","volume":"38","author":"Labbadia J.","year":"2013","unstructured":"Labbadia J.; Morimoto R.I.; Huntington\u2019s disease: Underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 2013,38(8),378-385","journal-title":"Trends Biochem Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1750-3639.1997.tb00893.x","volume":"7","author":"Robitaille Y.","year":"1997","unstructured":"Robitaille Y.; Lopes-Cendes I.; Becher M.; Rouleau G.; Clark A.W.; The neuropathology of CAG repeat diseases: Review and update of genetic and molecular features. Brain Pathol 1997,7(3),901-926","journal-title":"Brain Pathol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"Lee J.M.","year":"2012","unstructured":"Lee J.M.; Ramos E.M.; Lee J.H.; Gillis T.; Mysore J.S.; Hayden M.R.; Warby S.C.; Morrison P.; Nance M.; Ross C.A.; Margolis R.L.; Squitieri F.; Orobello S.; Di Donato S.; Gomez-Tortosa E.; Ayuso C.; Suchowersky O.; Trent R.J.; McCusker E.; Novelletto A.; Frontali M.; Jones R.; Ashizawa T.; Frank S.; Saint-Hilaire M.H.; Hersch S.M.; Rosas H.D.; Lucente D.; Harrison M.B.; Zanko A.; Abramson R.K.; Marder K.; Sequeiros J.; Paulsen J.S.; Landwehrmeyer G.B.; Myers R.H.; MacDonald M.E.; Gusella J.F.; CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012,78(10),690-695","journal-title":"Neurology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.drudis.2014.03.005","volume":"19","author":"Burgunder J.M.","year":"2014","unstructured":"Burgunder J.M.; Genetics of Huntington\u2019s disease and related disorders. Drug Discov Today 2014,19(7),985-989","journal-title":"Drug Discov Today"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","volume":"1","author":"Myers R.H.","year":"2004","unstructured":"Myers R.H.; Huntington\u2019s disease genetics. NeuroRx 2004,1(2),255-262","journal-title":"NeuroRx"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-319-89330-3_8","author":"Cavanna A.E.","year":"2018","unstructured":"Cavanna A.E.;  Motion and Emotion 2018,93-99","journal-title":"Motion and Emotion"},{"key":"ref=55","author":"Nordick K.","year":"2019","unstructured":"Nordick K.; Al Khalili Y.;  StatPearls Internet2019","journal-title":"StatPearls"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"c3109","DOI":"10.1136\/bmj.c3109","volume":"340","author":"Novak M.J.","year":"2010","unstructured":"Novak M.J.; Tabrizi S.J.; Huntington\u2019s disease. BMJ 2010,340,c3109","journal-title":"BMJ"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-981-13-0944-1_5","author":"Ign\u00e1cio Z.M.","year":"2019","unstructured":"Ign\u00e1cio Z.M.; Quevedo J.; R\u00e9us G.Z.;  Pathology, Prevention and therapeutics of neurodegenerative disease 2019,49-60","journal-title":"Pathology, Prevention and therapeutics of neurodegenerative disease"},{"key":"ref=58","first-page":"(64)","author":"Bates G.","year":"2014","unstructured":"Bates G.; Tabrizi S.; Jones L.;  Huntington's disease 2014,(64)","journal-title":"Huntington's disease"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/BJ20071619","volume":"412","author":"Imarisio S.","year":"2008","unstructured":"Imarisio S.; Carmichael J.; Korolchuk V.; Chen C.W.; Saiki S.; Rose C.; Krishna G.; Davies J.E.; Ttofi E.; Underwood B.R.; Rubinsztein D.C.; Huntington\u2019s disease: From pathology and genetics to potential therapies. Biochem J 2008,412(2),191-209","journal-title":"Biochem J"},{"key":"ref=60","first-page":"258","author":"Hedreen J.C.","year":"2011","unstructured":"Hedreen J.C.; Roos R.A.; Huntington\u2019s disease Neurodegeneration: The molecular pathology of dementia and movement disorders 2011,258-72","journal-title":"Neurodegeneration: The molecular pathology of dementia and movement disorders"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","volume":"20","author":"Li S.H.","year":"2004","unstructured":"Li S.H.; Li X.J.; Huntingtin-protein interactions and the pathogenesis of Huntington\u2019s disease. Trends Genet 2004,20(3),146-154","journal-title":"Trends Genet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/0959-4388(95)80072-7","volume":"5","author":"Gusella J.F.","year":"1995","unstructured":"Gusella J.F.; MacDonald M.E.; Huntington\u2019s disease: CAG genetics expands neurobiology. Curr Opin Neurobiol 1995,5(5),656-662","journal-title":"Curr Opin Neurobiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-319-08927-0_9","author":"Bobori C.","year":"2015","unstructured":"Bobori C.;  GeNeDis 2014 2015,59-65","journal-title":"GeNeDis 2014"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"Rawlins M.D.","year":"2016","unstructured":"Rawlins M.D.; Wexler N.S.; Wexler A.R.; Tabrizi S.J.; Douglas I.; Evans S.J.; Smeeth L.; The prevalence of Huntington\u2019s disease. Neuroepidemiology 2016,46(2),144-153","journal-title":"Neuroepidemiology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","volume":"107","author":"Zheng Z.","year":"2012","unstructured":"Zheng Z.; Diamond M.I.; Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci [). Academic Press.].2012,107,189-214","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1212\/WNL.38.5.769","volume":"38","author":"Lanska D.J.","year":"1988","unstructured":"Lanska D.J.; Lavine L.; Lanska M.J.; Schoenberg B.S.; Huntington\u2019s disease mortality in the United States. Neurology 1988,38(5),769-772","journal-title":"Neurology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF00194305","volume":"89","author":"Harper P.S.","year":"1992","unstructured":"Harper P.S.; The epidemiology of Huntington\u2019s disease. Hum Genet 1992,89(4),365-376","journal-title":"Hum Genet"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/hmg\/ddm217","volume":"16","author":"Atwal R.S.","year":"2007","unstructured":"Atwal R.S.; Xia J.; Pinchev D.; Taylor J.; Epand R.M.; Truant R.; Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007,16(21),2600-2615","journal-title":"Hum Mol Genet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e78490","DOI":"10.1371\/journal.pone.0078490","volume":"8","author":"Borlongan C.V.","year":"2013","unstructured":"Borlongan C.V.; Burns J.; Tajiri N.; Stahl C.E.; Weinbren N.L.; Shojo H.; Sanberg P.R.; Emerich D.F.; Kaneko Y.; van Loveren H.R.; Epidemiological survey-based formulae to approximate incidence and prevalence of neurological disorders in the United States: A meta-analysis. PLoS One 2013,8(10),e78490","journal-title":"PLoS One"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/cge.12574","volume":"89","author":"Squitieri F.","year":"2016","unstructured":"Squitieri F.; Griguoli A.; Capelli G.; Porcellini A.; D\u2019Alessio B.; Epidemiology of Huntington disease: First post-HTT gene analysis of prevalence in Italy. Clin Genet 2016,89(3),367-370","journal-title":"Clin Genet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0168-9525(01)02625-7","volume":"18","author":"Rubinsztein D.C.","year":"2002","unstructured":"Rubinsztein D.C.; Lessons from animal models of Huntington\u2019s disease. Trends Genet 2002,18(4),202-209","journal-title":"Trends Genet"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/187152710791556113","volume":"9","author":"Fernandez-Checa J.C.","year":"2010","unstructured":"Fernandez-Checa J.C.; Fernandez A.; Morales A.; Mari M.; Garcia-Ruiz C.; Colell A.; Oxidative stress and altered mitochondrial function in neurodegenerative diseases: Lessons from mouse models. CNS Neurol Disord Drug Targets 2010,9(4),439-454","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/187152710791556104","volume":"9","author":"Hirth F.","year":"2010","unstructured":"Hirth F.; Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol Disord Drug Targets 2010,9,504-523","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/187152709788680689","volume":"8","author":"Orsucci D.","year":"2009","unstructured":"Orsucci D.; Calsolaro V.; Mancuso M.; Siciliano G.; Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009,8(3),222-231","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/187152710793237377","volume":"9","author":"Pruss RM","year":"2010","unstructured":"Pruss RM; Phenotypic screening strategies for neurodegenerative diseases: A pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol Disord Drug Targets 2010,9(6),693-700","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/187152710791556186","volume":"9","author":"Skaper D","year":"2010","unstructured":"Skaper D; Giusti P; Transgenic mouse models of Parkinson's disease and Huntington's disease. CNS Neurol Disord Drug Targets 2010,9(4),455-470","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/1568007054546081","volume":"4","author":"Rego A.C.","year":"2005","unstructured":"Rego A.C.; de Almeida L.P.; Molecular targets and therapeutic strategies in Huntington\u2019s disease. Curr Drug Targets CNS Neurol Disord 2005,4(4),361-381","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/187152710793237421","volume":"9","author":"Xilouri M.","year":"2010","unstructured":"Xilouri M.; Stefanis L.; Autophagy in the central nervous system: Implications for neurodegenerative disorders. CNS Neurol Disord Drug Targets 2010,9(6),701-719","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/187152711795563967","volume":"10","author":"Mazurova Y.","year":"2011","unstructured":"Mazurova Y.; Guncova I.; Latr I.; Rudolf E.; Intervention of proliferation and differentiation of endogenous neural stem cells in the neurodegenerative process of Huntington's disease phenotype. CNS Neurol Disord Drug Targets 2011,10,486-499","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"Langbehn D.R.","year":"2004","unstructured":"Langbehn D.R.; Brinkman R.R.; Falush D.; Paulsen J.S.; Hayden M.R.; A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet 2004,65(4),267-277","journal-title":"Clin Genet"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1590\/1516-4446-2013-1159","volume":"35","author":"Schlachetzki J.C.","year":"2013","unstructured":"Schlachetzki J.C.; Saliba S.W.; Oliveira A.C.P.D.; Studying neurodegenerative diseases in culture models. Br J Psychiatry 2013,35(Suppl. 2),S92-S100","journal-title":"Br J Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-4939-7825-0_5","volume":"1780","author":"Chongtham A.","year":"2018","unstructured":"Chongtham A.; Barbaro B.; Filip T.; Syed A.; Huang W.; Smith M.R.; Marsh J.L.; Nonmammalian models of Huntington\u2019s disease. Methods Mol Biol 2018,1780,75-96","journal-title":"Methods Mol Biol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuro.2008.04.006","volume":"29","author":"Peterson R.T.","year":"2008","unstructured":"Peterson R.T.; Nass R.; Boyd W.A.; Freedman J.H.; Dong K.; Narahashi T.; Use of non-mammalian alternative models for neurotoxicological study. Neurotoxicology 2008,29(3),546-555","journal-title":"Neurotoxicology"},{"key":"ref=84","first-page":"58","volume":"44","author":"Guhad F.","year":"2005","unstructured":"Guhad F.; Introduction to the 3Rs (refinement, reduction and replacement). Contemp Top Lab Anim Sci 2005,44(2),58-59","journal-title":"Contemp Top Lab Anim Sci"},{"key":"ref=85","first-page":"63","volume":"20","author":"Rusche B.","year":"2003","unstructured":"Rusche B.; The 3Rs and animal welfare - conflict or the way forward? ALTEX 2003,20(Suppl. 1),63-76","journal-title":"ALTEX"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2015.03.040","volume":"759","author":"Graham M.L.","year":"2015","unstructured":"Graham M.L.; Prescott M.J.; The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease. Eur J Pharmacol 2015,759,19-29","journal-title":"Eur J Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jsps.2013.11.002","volume":"23","author":"Doke S.K.","year":"2015","unstructured":"Doke S.K.; Dhawale S.C.; Alternatives to animal testing: A review. Saudi Pharm J 2015,23(3),223-229","journal-title":"Saudi Pharm J"},{"key":"ref=88","volume":"30","author":"Worth A.","year":"2002","unstructured":"Worth A.; Balls M.; Alternative (non-animal) methods for chemicals testing: Current status and future prospects a report prepared by ECVAM and the ECVAM Working Group on Chemicals. ATLA-NOTTINGHAM 2002,30","journal-title":"ATLA-NOTTINGHAM"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1410E","DOI":"10.2903\/sp.efsa.2018.EN-1410","volume":"15","author":"Masjosthusmann S.","year":"2018","unstructured":"Masjosthusmann S.; Barenys M.; El\u2010Gamal M.; Geerts L.; Gerosa L.; Gorreja A.; K\u00fchne B.; Marchetti N.; Tigges J.; Viviani B.; Witters H.; Literature review and appraisal on alternative neurotoxicity testing methods. EFSA Supporting Publications 2018,15(4),1410E","journal-title":"EFSA Supporting Publications"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/ijms19082398","volume":"19","author":"Rosas-Arellano A.","year":"2018","unstructured":"Rosas-Arellano A.; Estrada-Mondrag\u00f3n A.; Pi\u00f1a R.; Mantellero C.A.; Castro M.A.; The tiny drosophila melanogaster for the biggest answers in huntington\u2019s disease. Int J Mol Sci 2018,19(8),2398","journal-title":"Int J Mol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"Pouladi M.A.","year":"2013","unstructured":"Pouladi M.A.; Morton A.J.; Hayden M.R.; Choosing an animal model for the study of Huntington\u2019s disease. Nat Rev Neurosci 2013,14(10),708-721","journal-title":"Nat Rev Neurosci"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1371\/journal.pbio.0060053","volume":"6","author":"Chan H.Y.E.","year":"2008","unstructured":"Chan H.Y.E.; Bonini N.M.; Drosophila models of human neurodegenerative disease. Cell Death Differ 2000; 7: 1075-1080. Jackson, GR. Guide to understanding Drosophila models of neurodegenerative diseases. PLoS Biol 2008,6(2),53","journal-title":"PLoS Biol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10158-005-0005-8","volume":"5","author":"Kretzschmar D.","year":"2005","unstructured":"Kretzschmar D.; Neurodegenerative mutants in Drosophila: a means to identify genes and mechanisms involved in human diseases? Invert Neurosci 2005,5(3-4),97-109","journal-title":"Invert Neurosci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1871527317666180508123050","volume":"17","author":"Beg T.","year":"2018","unstructured":"Beg T.; Jyoti S.; Naz F.; Rahul ; Ali F.; Ali S.K.; Reyad A.M.; Siddique Y.H.; Protective effect of kaempferol on the transgenic Drosophila model of Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2018,17(6),421-429","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jab.2017.11.002","volume":"16","author":"Siddique Y.H.","year":"2018","unstructured":"Siddique Y.H.; Naz F.; Khan W.; Jyoti S.; Singh B.R.; Naqvi A.H.; Effect of pramipexole alginate nanodispersion (PAND) on the transgenic Drosophila expressing human alpha synuclein in the brain. J Appl Biomed 2018,16,111-119","journal-title":"J Appl Biomed"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"e17760","DOI":"10.1590\/s2175-97902018000317760","volume":"54","author":"Siddique Y.H.","year":"2018","unstructured":"Siddique Y.H.; Jyoti S.; Naz F.; Protective effect of luteolin on the transgenic Drosophila model of Parkinson\u2019s disease. Braz J Pharm Sci 2018,54(3),e17760","journal-title":"Braz J Pharm Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1556\/018.69.2018.2.1","volume":"69","author":"Siddique Y.H.","year":"2018","unstructured":"Siddique Y.H.; Naz F.; Jyoti S.; Effect of capsaicin on the oxidative stress and dopamine content in the transgenic Drosophila model of Parkinson\u2019s disease. Acta Biol Hung 2018,69(2),115-124","journal-title":"Acta Biol Hung"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/15376516.2018.1502386","volume":"28","author":"Khanam S.","year":"2018","unstructured":"Khanam S.; Naz F.; Ali F.; Smita Jyoti R.; Fatima A.; Khan W.; Singh B.R.; Naqvi A.H.; Siddique Y.H.; Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson\u2019s disease. Toxicol Mech Methods 2018,28(9),699-708","journal-title":"Toxicol Mech Methods"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/1574885513666180529114546","volume":"14","author":"Ara G.","year":"2019","unstructured":"Ara G.; Afzal M.; Smita J.; Effect of myricetin on the loss of dopaminergic neurons in the transgenic Drosophila model of Parkinson\u2019s disease. Curr Drug Ther 2019,14(1),58-64","journal-title":"Curr Drug Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2174\/1871527317666180820164250","volume":"17","author":"Fatima A.","year":"2018","unstructured":"Fatima A.; Jyoti S.; Siddique Y.H.; Models of Parkinson\u2019s disease with special emphasis on Drosophila melanogaster. CNS Neurol Disord Drug Targets 2018,17(10),757-766","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2174\/1871527318666190319141835","volume":"18","author":"Ali F.","year":"2019","unstructured":"Ali F.; Siddique Y.H.; Bioavailability and Pharmaco-therapeutic potential of luteolin in overcoming Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2019,18(5),352-365","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neulet.2019.04.047","volume":"705","author":"Fatima A.","year":"2019","unstructured":"Fatima A.; Rahul ; Siddique Y.H.; Role of tangeritin against cognitive impairments in transgenic Drosophila model of Parkinson\u2019s disease. Neurosci Lett 2019,705,112-117","journal-title":"Neurosci Lett"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e01483","DOI":"10.1016\/j.heliyon.2019.e01483","volume":"5","author":"Siddique Y.H.","year":"2019","unstructured":"Siddique Y.H.; Naz F.; Rahul ; Rashid M.; Tajuddin ; Effect of Majun Baladur on life span, climbing ability, oxidative stress and dopaminergic neurons in the transgenic Drosophila model of Parkinson\u2019s disease. Heliyon 2019,5(4),e01483","journal-title":"Heliyon"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000097303","volume":"3","author":"Cauchi R.J.","year":"2006","unstructured":"Cauchi R.J.; Van den Heuvel M.; The fly as a model for neurodegenerative diseases: Is it worth the jump? Neurodegener Dis 2006,3(6),338-356","journal-title":"Neurodegener Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev.genet.39.110304.095804","volume":"39","author":"Bilen J.","year":"2005","unstructured":"Bilen J.; Bonini N.M.; Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005,39,153-171","journal-title":"Annu Rev Genet"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1534\/genetics.111.133710","volume":"190","author":"Weiss K.R.","year":"2012","unstructured":"Weiss K.R.; Kimura Y.; Lee W.C.M.; Littleton J.T.; Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington\u2019s disease model. Genetics 2012,190(2),581-600","journal-title":"Genetics"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/hmg\/dds117","volume":"21","author":"Steinert J.R.","year":"2012","unstructured":"Steinert J.R.; Campesan S.; Richards P.; Kyriacou C.P.; Forsythe I.D.; Giorgini F.; Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet 2012,21(13),2912-2922","journal-title":"Hum Mol Genet"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/hmg\/ddq460","volume":"20","author":"Maher P.","year":"2011","unstructured":"Maher P.; Dargusch R.; Bodai L.; Gerard P.E.; Purcell J.M.; Marsh J.L.; ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet 2011,20(2),261-270","journal-title":"Hum Mol Genet"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/hmg\/ddt466","volume":"23","author":"Sajjad M.U.","year":"2014","unstructured":"Sajjad M.U.; Green E.W.; Miller-Fleming L.; Hands S.; Herrera F.; Campesan S.; Khoshnan A.; Outeiro T.F.; Giorgini F.; Wyttenbach A.; DJ-1 modulates aggregation and pathogenesis in models of Huntington\u2019s disease. Hum Mol Genet 2014,23(3),755-766","journal-title":"Hum Mol Genet"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1096\/fj.07-099689","volume":"22","author":"McLear J.A.","year":"2008","unstructured":"McLear J.A.; Lebrecht D.; Messer A.; Wolfgang W.J.; Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington\u2019s disease. FASEB J 2008,22(6),2003-2011","journal-title":"FASEB J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1021\/acschemneuro.8b00545","volume":"10","author":"Joshi A.S.","year":"2019","unstructured":"Joshi A.S.; Singh V.; Gahane A.; Thakur A.K.; Biodegradable nanoparticles containing mechanism based peptide inhibitors reduce polyglutamine aggregation in cell models and alleviate motor Symptoms in a drosophila model of huntington\u2019s disease. ACS Chem Neurosci 2019,10(3),1603-1614","journal-title":"ACS Chem Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000330505","volume":"9","author":"Bodai L.","year":"2012","unstructured":"Bodai L.; Pallos J.; Thompson L.M.; Marsh J.L.; Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington\u2019s disease. Neurodegener Dis 2012,9(2),104-106","journal-title":"Neurodegener Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/hmg\/11.21.2657","volume":"11","author":"Kazemi-Esfarjani P.","year":"2002","unstructured":"Kazemi-Esfarjani P.; Benzer S.; Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum Mol Genet 2002,11(21),2657-2672","journal-title":"Hum Mol Genet"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/hmg\/10.12.1307","volume":"10","author":"Sittler A.","year":"2001","unstructured":"Sittler A.; Lurz R.; Lueder G.; Priller J.; Lehrach H.; Hayer-Hartl M.K.; Hartl F.U.; Wanker E.E.; Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington\u2019s disease. Hum Mol Genet 2001,10(12),1307-1315","journal-title":"Hum Mol Genet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/JHD-150180","volume":"5","author":"Billes V.","year":"2016","unstructured":"Billes V.; Kov\u00e1cs T.; Hotzi B.; Manz\u00e9ger A.; Tagscherer K.; Koml\u00f3s M.; Tarn\u00f3ci A.; P\u00e1d\u00e1r Z.; Erd\u0151s A.; Bjelik A.; Legradi A.; Gulya K.; Guly\u00e1s B.; Vellai T.; AUTEN-67 (autophagy enhancer-67) hampers the progression of neurodegenerative symptoms in a Drosophila model of Huntington\u2019s disease. J Huntingtons Dis 2016,5(2),133-147","journal-title":"J Huntingtons Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","volume":"15","author":"Ehrnhoefer D.E.","year":"2006","unstructured":"Ehrnhoefer D.E.; Duennwald M.; Markovic P.; Wacker J.L.; Engemann S.; Roark M.; Legleiter J.; Marsh J.L.; Thompson L.M.; Lindquist S.; Muchowski P.J.; Wanker E.E.; Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet [of Huntington's disease].2006,15(18),2743-2751","journal-title":"Hum Mol Genet"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1073\/pnas.0505321102","volume":"102","author":"Wolfgang W.J.","year":"2005","unstructured":"Wolfgang W.J.; Miller T.W.; Webster J.M.; Huston J.S.; Thompson L.M.; Marsh J.L.; Messer A.; Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005,102(32),11563-11568","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1093\/hmg\/ddq249","volume":"19","author":"Besson M.T.","year":"2010","unstructured":"Besson M.T.; Dupont P.; Fridell Y.W.C.; Li\u00e9vens J.C.; Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet 2010,19(17),3372-3382","journal-title":"Hum Mol Genet"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1093\/hmg\/ddn255","volume":"17","author":"Mugat B.","year":"2008","unstructured":"Mugat B.; Parmentier M.L.; Bonneaud N.; Chan H.Y.E.; Maschat F.; Protective role of Engrailed in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet 2008,17(22),3601-3616","journal-title":"Hum Mol Genet"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e27408","DOI":"10.1371\/journal.pone.0027408","volume":"6","author":"Tamura T.","year":"2011","unstructured":"Tamura T.; Sone M.; Iwatsubo T.; Tagawa K.; Wanker E.E.; Okazawa H.; Ku70 alleviates neurodegeneration in Drosophila models of Huntington\u2019s disease. PLoS One 2011,6(11),e27408","journal-title":"PLoS One"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1038\/cddis.2014.581","volume":"6","author":"Khalil B.","year":"2015","unstructured":"Khalil B.; El Fissi N.; Aouane A.; Cabirol-Pol M.J.; Rival T.; Li\u00e9vens J.C.; PINK1-induced mitophagy promotes neuroprotection in Huntington\u2019s disease. Cell Death Dis 2015,6,e1617-e1617","journal-title":"Cell Death Dis"},{"key":"ref=122","first-page":"49","volume":"97","author":"Pasini M.E.","year":"2016","unstructured":"Pasini M.E.; Paiardi C.; Vernizzi L.; Valenza A.; Licata G.; Vitali T.; Vanoni M.A.; Gellera C.; Rizzetto M.; Taroni F.; Mariotti C.; B35 Glutamine Pandey, M. and Rajamma, U., 2018. Huntington\u2019s disease: The coming of age. J Genet 2016,97,49-664","journal-title":"J Genet"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"e0118765","DOI":"10.1371\/journal.pone.0118765","volume":"10","author":"Besson M.T.","year":"2015","unstructured":"Besson M.T.; Alegr\u00eda K.; Garrido-Gerter P.; Barros L.F.; Li\u00e9vens J.C.; Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model. PLoS One 2015,10(3),e0118765","journal-title":"PLoS One"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"14995","DOI":"10.1073\/pnas.1308535110","volume":"110","author":"Xiao G.","year":"2013","unstructured":"Xiao G.; Fan Q.; Wang X.; Zhou B.; Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. Proc Natl Acad Sci USA 2013,110(37),14995-15000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"6726874","DOI":"10.1155\/2018\/6726874","volume":"2018","author":"Arabit J.G.J.","year":"2018","unstructured":"Arabit J.G.J.; Elhaj R.; Schriner S.E.; Sevrioukov E.A.; Jafari M.; Rhodiola rosea improves lifespan, locomotion, and neurodegeneration in a Drosophila melanogaster model of Huntington\u2019s disease. BioMed Res Int 2018,2018,6726874","journal-title":"BioMed Res Int"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02088-w","volume":"9","author":"Aron R.","year":"2018","unstructured":"Aron R.; Pellegrini P.; Green E.W.; Maddison D.C.; Opoku-Nsiah K.; Wong J.S.; Daub A.C.; Giorgini F.; Finkbeiner S.; Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington\u2019s disease. Nat Commun 2018,9(1),1-14","journal-title":"Nat Commun"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.1523\/JNEUROSCI.0895-12.2012","volume":"32","author":"Sontag E.M.","year":"2012","unstructured":"Sontag E.M.; Lotz G.P.; Agrawal N.; Tran A.; Aron R.; Yang G.; Necula M.; Lau A.; Finkbeiner S.; Glabe C.; Marsh J.L.; Muchowski P.J.; Thompson L.M.; Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington\u2019s disease models. J Neurosci 2012,32(32),11109-11119","journal-title":"J Neurosci"},{"key":"ref=128","first-page":"1711","volume":"104","author":"Dwivedi V.","year":"2013","unstructured":"Dwivedi V.; Tripathi B.K.; Mutsuddi M.; Lakhotia S.C.; Ayurvedic Amalaki Rasayana and Rasa-Sindoor suppress neurodegeneration in fly models of Huntington\u2019s and Alzheimer\u2019s diseases. Curr Sci 2013,104,1711-1723","journal-title":"Curr Sci"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"104963","DOI":"10.1016\/j.nbd.2020.104963","volume":"143","author":"Wilton D.K.","year":"2020","unstructured":"Wilton D.K.; Stevens B.; The contribution of glial cells to Huntington's disease pathogenesis Neurobiol Dis 2020,143(104963),104963","journal-title":"Neurobiol Dis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"Campesan S.","year":"2011","unstructured":"Campesan S.; Green E.W.; Breda C.; Sathyasaikumar K.V.; Muchowski P.J.; Schwarcz R.; Kyriacou C.P.; Giorgini F.; The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol 2011,21(11),961-966","journal-title":"Curr Biol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1073\/pnas.1604453113","volume":"113","author":"Breda C.","year":"2016","unstructured":"Breda C.; Sathyasaikumar K.V.; Sograte Idrissi S.; Notarangelo F.M.; Estranero J.G.; Moore G.G.; Green E.W.; Kyriacou C.P.; Schwarcz R.; Giorgini F.; Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc Natl Acad Sci USA 2016,113(19),5435-5440","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"Steffan J.S.","year":"2001","unstructured":"Steffan J.S.; Bodai L.; Pallos J.; Poelman M.; McCampbell A.; Apostol B.L.; Kazantsev A.; Schmidt E.; Zhu Y.Z.; Greenwald M.; Kurokawa R.; Housman D.E.; Jackson G.R.; Marsh J.L.; Thompson L.M.; Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001,413(6857),739-743","journal-title":"Nature"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","volume":"46","author":"Jia H.","year":"2012","unstructured":"Jia H.; Pallos J.; Jacques V.; Lau A.; Tang B.; Cooper A.; Syed A.; Purcell J.; Chen Y.; Sharma S.; Sangrey G.R.; Darnell S.B.; Plasterer H.; Sadri-Vakili G.; Gottesfeld J.M.; Thompson L.M.; Rusche J.R.; Marsh J.L.; Thomas E.A.; Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease. Neurobiol Dis 2012,46(2),351-361","journal-title":"Neurobiol Dis"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","volume":"17","author":"Pallos J.","year":"2008","unstructured":"Pallos J.; Bodai L.; Lukacsovich T.; Purcell J.M.; Steffan J.S.; Thompson L.M.; Marsh J.L.; Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet 2008,17(23),3767-3775","journal-title":"Hum Mol Genet"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MCO.0000000000000134","volume":"18","author":"Gu F.","year":"2015","unstructured":"Gu F.; Chauhan V.; Chauhan A.; Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care 2015,18(1),89-95","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/ng.2732","volume":"45","author":"Mason R.P.","year":"2013","unstructured":"Mason R.P.; Casu M.; Butler N.; Breda C.; Campesan S.; Clapp J.; Green E.W.; Dhulkhed D.; Kyriacou C.P.; Giorgini F.; Glutathione peroxidase activity is neuroprotective in models of Huntington\u2019s disease. Nat Genet 2013,45(10),1249-1254","journal-title":"Nat Genet"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1073\/pnas.0400243101","volume":"101","author":"Lee W.C.M.","year":"2004","unstructured":"Lee W.C.M.; Yoshihara M.; Littleton J.T.; Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington\u2019s disease. Proc Natl Acad Sci USA 2004,101(9),3224-3229","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0896-6273(03)00594-4","volume":"40","author":"Gunawardena S.","year":"2003","unstructured":"Gunawardena S.; Her L.S.; Brusch R.G.; Laymon R.A.; Niesman I.R.; Gordesky-Gold B.; Sintasath L.; Bonini N.M.; Goldstein L.S.; Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003,40(1),25-40","journal-title":"Neuron"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"13662","DOI":"10.1523\/JNEUROSCI.4144-08.2008","volume":"28","author":"Her L.S.","year":"2008","unstructured":"Her L.S.; Goldstein L.S.; Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 2008,28(50),13662-13672","journal-title":"J Neurosci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"618127","DOI":"10.1155\/2011\/618127","volume":"2011","author":"Turturici G.","year":"2011","unstructured":"Turturici G.; Sconzo G.; Geraci F.; Hsp70 and its molecular role in nervous system diseases. Biochem Res Int 2011,2011,618127","journal-title":"Biochem Res Int"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1093\/hmg\/ddr314","volume":"20","author":"Guzhova I.V.","year":"2011","unstructured":"Guzhova I.V.; Lazarev V.F.; Kaznacheeva A.V.; Ippolitova M.V.; Muronetz V.I.; Kinev A.V.; Margulis B.A.; Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease. Hum Mol Genet 2011,20(20),3953-3963","journal-title":"Hum Mol Genet"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/192806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/192806\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/192806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:40:09Z","timestamp":1639564809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/192806\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":141,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527320666210412155508","relation":{},"ISSN":["1871-5273"],"issn-type":[{"type":"print","value":"1871-5273"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}